Ketone ester-enriched diet ameliorates motor and dopamine release deficits in MitoPark mice
Vikrant R. MahajaniD, Jacob A. NadeliD, Michael Todd KingiD, Robert J. PawloskyiD, Margaret I. Davis, Richard L. VeechiD, David M. LovingeriD, Armando G. SalinasiD
Abstract
BackgroundParkinsons disease is a progressive, neurodegenerative disease characterized by motor dysfunction and dopamine deficits. The MitoPark mouse recapitulates several facets of Parkinsons disease, including gradual development of motor deficits, which enables the study of potential therapeutic interventions. One therapeutic strategy involves decreasing the mitochondrial metabolic load by inducing ketosis and providing an alternative energy source for neurons, leading to decreased neuronal oxidative stress. ObjectiveWe assessed whether administration of a ketone ester-enriched diet would improve motor and dopamine release deficits in MitoPark mice. MethodsMotor function (rotarod and open field tests), dopamine release (fast-scan cyclic voltammetry), tissue dopamine levels (GC-MS), and dopamine neurons and axons (immunofluorescence) were assessed in MitoPark and control mice fed either the standard or ketone ester-enriched diets. ResultsWhen started on the ketone diet before motor dysfunction onset, MitoPark mice had preserved motor function relative to standard diet MitoPark mice. While the ketone ester enriched diet did not preserve dopamine neurons or striatal dopamine axons, dopamine release in ketone diet MitoPark mice was greater than standard diet MitoPark mice but less than control mice. In a follow up experiment, we began the ketone diet after motor dysfunction onset and observed a modest preservation of motor function in ketone diet MitoPark mice relative to standard diet MitoPark mice. ConclusionThe improvement in motor dysfunction indicates that a ketone ester enriched diet or ketone supplement may represent a promising adjunct treatment for Parkinsons disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 1.33
- Field percentile
- top 19%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Re-routing metabolism by the mitochondrial pyruvate carrier inhibitor MSDC-0160 attenuates neurodegeneration in a rat model of Parkinson's disease
David Mallet, Raphaël Goutaudier, … Sabrina Boulet·Molecular NeurobiologyPeer-reviewed·Jul 27, 2022
- Mitochondrial DNA damage in substantia nigra parscompacta astrocytes exacerbates dopaminergic neuron lossin a 6-hydroxydopamine mouse model of parkinsonism
Daniela A. Ayala, Grace M Hall, … Rahul Srinivasan·Cellular and Molecular NeurobiologyPeer-reviewed·Mar 19, 2026
- Characterization of Nonmotor Symptoms in the MitoPark Mouse Model of Parkinson's Disease
Monica Renee Langley, Shivani Ghaisas, … Anumantha G Kanthasamy·bioRxiv·Nov 2, 2020
- M5 positive allosteric modulation alleviates parkinsonian motor deficits
Nicole Chambers, Dominic Hall, … Mark S. Moehle·bioRxiv·Aug 21, 2025
- Preserved striatal innervation and motor function despite severe loss of nigral dopamine neurons following mitochondrial dysfunction induced by mtDNA mutations
Thomas Paß, Konrad M. Ricke, … Rudolf J. Wiesner·bioRxiv·Jul 7, 2023
- Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons
Aurélie Schwartzentruber, Camilla Boschian, … Heather Mortiboys·Scientific ReportsPeer-reviewed·Sep 23, 2020